Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea.
Frequently asked questions
What sector does Quratis Inc. (348080) operate in?
Quratis Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Quratis Inc. (348080) current stock price?
As of the latest data, Quratis Inc. stock price is ₩3,205, with a previous close of ₩3,225. Quratis Inc. lost -₩20 in the last trading session, representing a -0.62% loss.
What is Quratis Inc. (348080) current market capitalization?
Quratis Inc. market cap is approximately 41.07 billion.
What is Quratis Inc. (348080) EBITDA?
Quratis Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.20 billion.
Does Quratis Inc. (348080) pay dividends?
No. Quratis Inc. does not pay a dividend.
What is Quratis Inc. (348080) beta (volatility) score?
Quratis Inc. has a beta of -0.333, indicating lower volatility than the overall market.